Sentinel lymph node biopsy predicts systemic recurrence in digital papillary adenocarcinoma
Meredith K Bartelstein1, Eugenia Schwarzkopf2, Klaus J Busam3
1Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Background And Objectives:
Digital papillary adenocarcinoma (DPA) is a rare, aggressive neoplasm of sweat gland origin. It can recur at local, regional, or distant sites. There is limited knowledge about the role of sentinel lymph node biopsy (SLNB) in predicting recurrence in these patients. We present our experience with this uncommon tumor to evaluate the role of SLNB in predicting outcome.
Methods:
Medical records of all patients who underwent surgical treatment for biopsy-proven upper extremity DPA at the study institution were reviewed. Descriptive statistics and Fisher's exact test were used to analyze data.
Results:
Twenty-one patients were identified. Most patients were male (71%), and the median age was 51 years. SLNB was performed in 18 patients; three were positive for nodal metastatic disease (17%). At a median follow-up of 53 months, there were no local recurrences and two cases of systemic recurrence. No patient with a negative sentinel lymph node has evidence of metastasis or recurrence. Fisher's exact test demonstrated a significant association between a positive SLNB and recurrence (P = .02).
Conclusion:
SLNB revealed metastatic disease in 17% of patients with DPA and appears to predict systemic recurrence in this small series.
